Nanovibronix Stock Price, News & Analysis

NanoVibronix, Inc. (formerly trading under the ticker NAOV) is a medical technology company that has focused on both non-invasive and minimally invasive therapeutic systems for use across clinical and home care settings. According to company disclosures, the business has emphasized two primary technology platforms: acoustic-based therapeutic devices and an electromagnetic navigation system for feeding tube placement. The company has been headquartered in Tyler, Texas, with research and development activities based in Nesher and Tel-Aviv, Israel.

In December 2025, the company filed a Certificate of Amendment to change its corporate name from NanoVibronix, Inc. to ENvue Medical, Inc., and its common stock ceased trading under the ticker symbol NAOV and began trading on the Nasdaq Capital Market under the symbol FEED. This name and symbol change, reported in a Form 8-K, did not alter the rights of security holders and was implemented to align the corporate identity with the company’s strategic focus on its ENvue platform.

Core Technology Platforms

Company materials describe two main platforms:

• Acoustic-based therapeutic technologies: This platform includes devices such as PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
• ENvue™ Navigation Platform: Developed and operated by ENvue Medical entities, this is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. Company descriptions state that ENvue is FDA 510(k) cleared for adult use and provides real-time bedside visualization of tube movement to support informed decision-making during feeding tube placement procedures. Public statements also reference potential future expansion of the platform into pediatric and vascular access applications.

Strategic Shift and Rebranding

In a shareholder letter and subsequent press releases, the company identified the ENvue feeding-tube placement system as its strongest and most scalable growth platform. Management communications explain that ENvue was merged into NanoVibronix in early 2025 and that the company’s strategy has been to focus on scaling hospital utilization, strengthening its commercial footprint, and building a broader enteral-feeding ecosystem around the ENvue platform.

The rebranding to ENvue Medical, Inc. and the change of ticker symbol to FEED were described as steps intended to reflect this strategic direction, emphasizing precision enteral access and navigation technology. At the same time, the company has indicated that it is considering strategic alternatives for certain legacy NanoVibronix technologies, while continuing to reference PainShield and UroShield as part of its acoustic-based therapeutic portfolio.

Product and Technology Highlights

• PainShield®: Cited in company descriptions as an acoustic-based therapeutic device that uses low-intensity surface acoustic wave technology and is intended to treat pain in home or care environments.
• UroShield® and UroShield® Kit: Described as non-invasive devices designed to reduce catheter-associated urinary tract infections (CAUTIs) and catheter blockages by applying low-frequency ultrasonic energy to urinary catheters, helping to inhibit biofilm formation. Company news reports that the UroShield Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling prescription reimbursement across the UK, and that the company has an exclusive distribution relationship with Peak Medical in that market.
• ENvue™ Navigation Platform: Presented as a minimally invasive electromagnetic navigation system for feeding tube placement in adult patients. Company communications emphasize real-time visualization of tube movement at the bedside and describe the system as a platform that may support future applications, such as pediatric use and vascular access procedures, subject to development and regulatory pathways.
• Training and support tools: The company has announced "Oscar," described as an advanced training aid introduced through its ENvue Medical division. Oscar is intended to provide clinicians and educators with a standardized, repeatable approach to practicing naso-enteral feeding procedures. Company statements clarify that Oscar is not classified as a medical device and is positioned as a teaching aid to support adoption of the ENvue system and related training programs.

Geographic Footprint and Operations

Public filings and press releases indicate that the company’s principal executive offices have been located in Tyler, Texas. Research and development functions are described as being conducted in Nesher and Tel-Aviv, Israel. For the ENvue Navigation Platform, company descriptions reference offices in Arlington Heights, Illinois, and Tel-Aviv, Israel.

Regulatory and Capital Markets Context

NanoVibronix, Inc. has been listed on the Nasdaq Capital Market, with its common stock previously trading under the symbol NAOV. In August 2025, the company implemented a 1-for-10 reverse stock split of its common stock, as disclosed in a Form 8-K filing. The reverse split was approved by stockholders at a special meeting and was effected through a Certificate of Amendment to the company’s Amended and Restated Certificate of Incorporation.

The company has used a combination of registered direct offerings and private placements to raise capital, as described in several Form 8-K filings. These transactions have included the issuance of common stock, pre-funded warrants, and Series H Convertible Preferred Stock, along with associated warrants, with stated purposes that include working capital, repayment or redemption of certain outstanding securities, and broader corporate purposes.

Corporate Governance and Shareholder Communications

Proxy materials and SEC filings show that NanoVibronix, Inc. has held annual and special meetings of stockholders, conducted virtually via live webcast. The company has sought stockholder approval for matters such as director elections, auditor ratification, amendments to long-term incentive plans, and authorization of certain equity issuances under Nasdaq rules.

In a shareholder letter, the company’s leadership outlined its review of operations and market opportunities, emphasizing the decision to prioritize the ENvue feeding-tube placement system and to explore strategic alternatives for legacy assets. The letter also discussed the company’s view of the enteral-feeding market and the potential for ENvue to serve as a broader navigation platform across multiple clinical applications, while noting that some of these opportunities relate to future development.

Historical Context for NAOV Ticker

For investors and researchers reviewing the historical NAOV ticker, it is important to recognize that NAOV represents the period when the company operated under the NanoVibronix, Inc. name and before the symbol change to FEED. The business focus during this period, as reflected in public disclosures, centered on acoustic-based therapeutic technologies (PainShield and UroShield) and the integration and expansion of the ENvue Navigation Platform. Following the name and ticker change effective December 12, 2025, ongoing trading and disclosures occur under the ENvue Medical, Inc. identity and the FEED symbol on Nasdaq.